Skip to main content
. Author manuscript; available in PMC: 2016 Mar 14.
Published in final edited form as: Curr Neurol Neurosci Rep. 2009 May;9(3):254–262. doi: 10.1007/s11910-009-0037-2

Figure 2.

Figure 2

MRI of a patient with a recurrent left temporal glioblastoma. Contrast-enhanced MRI prior to therapy with bevacizumab and irinotecan (A) and 6 months later (B). Fluid-attenuated inversion recovery (FLAIR) prior to therapy with bevacizumab and irinotecan (C) and 6 months later (D). Note the remarkable decrease in contrast enhancement and reduction in FLAIR hyperintensity with decreased mass effect on the lateral ventricle.